Last reviewed · How we verify
E7449 plus carboplatin and paclitaxel — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
E7449 plus carboplatin and paclitaxel (E7449 plus carboplatin and paclitaxel) — Eisai Limited.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| E7449 plus carboplatin and paclitaxel TARGET | E7449 plus carboplatin and paclitaxel | Eisai Limited | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- E7449 plus carboplatin and paclitaxel CI watch — RSS
- E7449 plus carboplatin and paclitaxel CI watch — Atom
- E7449 plus carboplatin and paclitaxel CI watch — JSON
- E7449 plus carboplatin and paclitaxel alone — RSS
Cite this brief
Drug Landscape (2026). E7449 plus carboplatin and paclitaxel — Competitive Intelligence Brief. https://druglandscape.com/ci/e7449-plus-carboplatin-and-paclitaxel. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab